Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Truist Financial Reaffirms Their Buy Rating on Elevance Health (ELV)

Tipranks - Tipranks - Thu Jan 29, 2:08AM CST

In a report released yesterday, David S Macdonald from Truist Financial reiterated a Buy rating on Elevance Health. The company’s shares closed yesterday at $322.92.

Claim 50% Off TipRanks Premium

According to TipRanks, S Macdonald is a 5-star analyst with an average return of 11.8% and a 59.48% success rate. S Macdonald covers the Healthcare sector, focusing on stocks such as Radnet, PACS Group Inc, and Centene.

Currently, the analyst consensus on Elevance Health is a Strong Buy with an average price target of $396.36, implying a 22.74% upside from current levels. In a report released yesterday, Bernstein also maintained a Buy rating on the stock with a $431.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Elevance Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $50.71 billion and a net profit of $1.19 billion. In comparison, last year the company earned a revenue of $45.15 billion and had a net profit of $1.02 billion

Read More on ELV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).